Advanced search
Publication Cover
Substance Abuse and Rehabilitation Volume 10, 2019 - Issue
Submit an article Journal homepage
632
Views
18
CrossRef citations to date
0
Altmetric
Review

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation

Walter Ling1 UCLA Department of Family Medicine, Center for Behavioral and Addiction Medicine, Los Angeles, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0664-5099
ORCID Icon,
Steve Shoptaw1 UCLA Department of Family Medicine, Center for Behavioral and Addiction Medicine, Los Angeles, CA, USA
&
David Goodman-Meza2 UCLA Department of Medicine, Division of Infectious Diseases, Los Angeles, CA, USAORCID Iconhttps://orcid.org/0000-0001-9382-3564
ORCID Icon
Pages 69-78 | Published online: 29 Nov 2019

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ari B. Cuperfain, Gali Katznelson, Tianna Costa, Patrick Wong, Narges Beyraghi, Tony P. George, Michelle R. Lofwall & Nitin Chopra. (2023) Factors to guide the use of extended-release buprenorphine formulations for specific patient populations. Journal of Substance Use 0:0, pages 1-7.
Read now
Allison M. Gustavson, Adam J. Gordon, Marie E. Kenny, Haley McHenry, Julie Gronek, Princess E. Ackland & Hildi J. Hagedorn. (2020) Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Substance Abuse 41:4, pages 413-418.
Read now

Articles from other publishers (16)

Suyash Deodhar, Benson Edagwa & Brady Sillman. (2023) Challenges in ultralong-acting formulation development: eyes on buprenorphine. NeuroImmune Pharmacology and Therapeutics 0:0.
Crossref
Celine M. Laffont, Eliford Ngaimisi, Mathangi Gopalakrishnan, Vijay Ivaturi, Malcolm Young, Mark K. Greenwald & Christian Heidbreder. (2022) Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Frontiers in Pharmacology 13.
Crossref
Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam M. Kaye & Alan D Kaye. (2022) Buprenorphine and its formulations: a comprehensive review. Health Psychology Research 10:3.
Crossref
Albert Dahan, Maarten van Lemmen, Simone Jansen, Pieter Simons & Rutger van der Schrier. (2022) Buprenorphine: a treatment and cause of opioid-induced respiratory depression. British Journal of Anaesthesia 128:3, pages 402-404.
Crossref
Wei Li, Jie Tang, Dennis Lee, Thomas R. Tice, Steven P. Schwendeman & Mark R. Prausnitz. (2022) Clinical translation of long-acting drug delivery formulations. Nature Reviews Materials 7:5, pages 406-420.
Crossref
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good & Rif S. El-Mallakh. (2021) New Antipsychotic Medications in the Last Decade. Current Psychiatry Reports 23:12.
Crossref
Elizabeth C. Saunders, Alan J. Budney, Patricia Cavazos-Rehg, Emily Scherer & Lisa A. Marsch. (2021) Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids. Preventive Medicine 152, pages 106783.
Crossref
Michael Soyka & Andreas G Franke. (2021) Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations. World Journal of Psychiatry 11:9, pages 543-552.
Crossref
Daniel Wolfe & Roxanne Saucier. (2021) Reprint of: Biotechnologies and the future of opioid addiction treatments. International Journal of Drug Policy 94, pages 103273.
Crossref
Kristen Huntley, Emily Einstein, Terri Postma, Anita Thomas, Shari Ling & Wilson Compton. (2021) Advancing emergency department–initiated buprenorphine. Journal of the American College of Emergency Physicians Open 2:3.
Crossref
Juliane Mielau, Marc Vogel, Stefan Gutwinski & Inge Mick. (2021) New Approaches in Drug Dependence: Opioids. Current Addiction Reports 8:2, pages 298-305.
Crossref
Benjamin Rolland, Benoit Trojak, Mikail Nourredine, Jérôme Bachellier, Mathieu Chappuy, Patrick Bendimerad, Margaux Kosim, Peter Hjelmström, Fadi Meroueh, Philippe Nubukpo & Georges Brousse. (2021) Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug and Alcohol Dependence 220, pages 108492.
Crossref
Daniel Wolfe & Roxanne Saucier. (2021) Biotechnologies and the future of opioid addiction treatments. International Journal of Drug Policy 88, pages 103041.
Crossref
Michael Soyka. (2020) Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. Pharmacopsychiatry 54:01, pages 18-22.
Crossref
Mathieu Chappuy, Benoit Trojak, Philippe Nubukpo, Jérôme Bachellier, Patrick Bendimerad, Georges Brousse & Benjamin Rolland. (2020) Prolonged-release buprenorphine formulations: Perspectives for clinical practice. Therapies 75:5, pages 397-406.
Crossref
Mathieu Chappuy, Benoit Trojak, Philippe Nubukpo, Jérôme Bachellier, Patrick Bendimerad, Georges Brousse & Benjamin Rolland. (2020) Buprénorphine d’action prolongée : quelles perspectives pour la pratique clinique ?. Therapies.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.